ABOUT BIOBRIDGE
BioBridge Solutions delivers innovative expertise in the biotechnology sector, helping your business grow through three key service areas:
Licensing: We facilitate connections between organizations seeking to license in or out innovative, generic, and biosimilar products. With our broad network and practical experience, we help partners monetize technologies and platforms efficiently.
Investment: BioBridge Solutions supports companies looking to acquire or divest development and manufacturing sites or life science businesses. We also offer co-development and private equity investment opportunities to increase your portfolio and optimize your operations.
CDMO: Through our partnerships with select CDMOs, we provide resources for development and commercial manufacturing in small molecule synthesis, oral solid dosage, sterile injectables, and biological drug substances. BioBridge Solutions guides you from initial discussions to contract finalization, ensuring smooth business development and direct engagement with CDMOs.
INDUSTRY INSIGHTS
-
![api-clinicial-tech-gettyimages-2149749988-170667a]( "Should Platform Biotech Companies Partner, Sell, Or License Their Technology?")
Platform biotech companies face critical choices on partnering, licensing, or selling technology—decisions that shape focus, valuation, and long‑term success beyond scientific innovation alone.
-
![GettyImages-952307842-biobanking-deep freeze-biological sample]( "How Asia and Europe Are Reshaping Biologics Manufacturing")
As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.
-
![Data Analytics, medical report-healthcare, teamwork-GettyImages-1483251775]( "Biosimilars – From An Executive Perspective")
An experienced industry leader shares insights on how biosimilars are reshaping healthcare through scale, manufacturing discipline, supply reliability, and long‑term commercial strategy.
-
![data-driven-biotech-GettyImages-2240941809]( "Moving Beyond Known Targets")
A pioneering perspective explores how new scientific thinking, physics‑based insights, and bold leadership are expanding the druggable universe and opening therapeutic paths once thought impossible.
CONTACT INFORMATION
BioBridge
Graesmarken 3
Soeborg, 2860
DENMARK
Phone: +45 5230-5533
Contact: Jonas Mortensen
SOLUTIONS
-
![450_300-img002 (1)]( "The Biosimilar Market Reality: Expansion, Risk, And Consolidation")
An executive view on how biosimilar misconceptions around demand, risk, and cost drove market crowding, manufacturing pressure, and eventual consolidation across the industry.
-
![trialkit-api-GettyImages-2223712653]( "A Bridge To Global Small Molecule Manufacturing")
Integrated global small‑molecule development and manufacturing solutions spanning chemistry, analytics, scale‑up, and commercial API supply, designed to reduce CMC risk and accelerate progress.
-
![GettyImages-163720603 tablet press, OSD]( "From Formulation To Global Supply: Mastering Oral Solid Development")
A global, integrated approach to oral solid dosage development combines formulation science, advanced delivery, and scalable manufacturing to support efficient clinical progress and reliable supply.
-
![GettyImages-1409734937-3d-rendering-rna-dna]( "Cracking The Code Of RNA Delivery")
Advanced lipid nanoparticle strategies are transforming RNA therapeutics by enabling faster optimization, precise tissue targeting, and access to biological targets once considered unreachable.
-
![biotechnology, Global Networking, Research, Development, Innovation, Advancing Smart Solutions-GettyImages-2123154659]( "Where The Right Assets Meet The Right Partners")
A network‑driven licensing approach helps biopharma organizations unlock asset value, strengthen pipelines, and execute in‑licensing and out‑licensing deals with greater speed and confidence.
-
![pharma-partners-GettyImages-2182052451]( "Unlocking Strategic Value Across The Biopharma Landscape")
A strategic approach to divestments and acquisitions helps biopharma organizations realign portfolios, accelerate growth, and connect the right assets with the right partners globally.
-
![cmo-biologics-GettyImages-1327624070]( "From Discovery To Delivery: A Smarter Path For Scaling Biologics")
A unified global model streamlines biologics from discovery to commercial supply, integrating development, manufacturing, advanced modalities, and flexible partnerships worldwide.
